![MVOA for detection of residual virus.](JIAS-18-20320-g001){#F0001_20320}

![Individual correlations matrix.](JIAS-18-20322-g001){#F0002_20322}

###### 

Adjusted summary correlations

  Anti-HIV antibody response   R      P
  ---------------------------- ------ -------
  loggp120                     0.80   0.009
  loggp41                      0.73   0.042
  logrt                        0.82   0.007
  logintegrase                 0.70   0.053
  logpr                        0.60   0.199
  logma                        0.54   0.340
  logp24                       0.41   0.679
  All                          0.82   0.039

![Survival to one year by CD8+ T-cell activation.](JIAS-18-20330-g001){#F0003_20330}

###### 

Characteristics of women and foetal ultrasound measurement

  Characteristics of pregnant women           TDF-exposed since conception (n=226)   TDF-exposed for \>4 weeks and initiated after first trimester (n=232)   TDF-exposed for \<4 weeks or TDF-unexposed (n=572)   p
  ------------------------------------------- -------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------- ---------
  Age of mother, years                        31 (27--34)                            27 (23--32)                                                             28 (25--32)                                          \<0.001
  GA, weeks                                   20 (14--28)                            21 (14--28)                                                             21 (16--27)                                          0.805
  Maternal BMI at enrolment, kg/m^2^          29.14 (25.81--33.91)                   28.50 (25.00--33.75)                                                    28.63 (25.15--34.24)                                 0.790
  CD4 cell count, cells/mm^3^                 399 (273--523)                         360 (239--478)                                                          340 (232--507)                                       0.015
  Log HIV RNA level at enrolment              1.59 (1.59--1.59)                      4.13 (3.52--4.57)                                                       3.99 (3.37--4.65)                                    \<0.001
  Number of women with \>2 ultrasound scans   147 (64.8)                             126 (54.3)                                                              479 (83.6)                                           0.001
  Characteristics of ultrasound scans         (n=408)                                (n=581)                                                                 (n=968)                                              p value
  Femur length z score                        0.32 (−0.03, 0.70)                     0.30 (−0.03, 0.63)                                                      0.33 (−0.07, 0.79)                                   0.570
  Humerus length z score                      0.13 (−0.29, 0.59)                     0.32 (−0.04, 0.59)                                                      0.05 (−0.33, 0.46)                                   0.832

###### 

Incidence of TB by time following IPT exposure

                IPT unexposed (n=2689)   IPT exposed (n=776)   Incidence rate ratio (95% CI)                                                                     
  ------------- ------------------------ --------------------- ------------------------------- ----------------- ------------------- ------- ------------------- -------
  Overall       318/8022                 4.0 (3.6--4.4)        54/1886                         2.9 (2.2--3.7)    0.72 (0.53--0.99)   0.042   0.77 (0.57--1.0)    0.070
  0--1 year     151/2672                 5.7 (4.8--6.6)        16/615                          1.6 (1.6--4.2)    0.46 (0.26--0.80)   0.006   0.60 (0.36--0.98)   0.042
  ≥1--2 years   75/2138                  3.5 (2.8--4.4)        20/519                          3.9 (2.5--6.0)    1.1 (0.63--1.9)     0.740   1.1 (0.67--1.8)     0.733
  ≥2--3 years   47/1362                  3.5 (2.6--4.6)        10/301                          3.3 (1.8--6.2)    0.96 (0.50--1.9)    0.880   0.95 (0.51--1.8)    0.880
  ≥3 years      45/1851                  2.4 (18--3.3)         8/451                           1.8 (0.89--3.7)   0.73 (0.30--1.6)    0.413   0.73 (0.34--1.6)    0.394

![Time to incident TB by IPT and HAART exposure.](JIAS-18-20334-g001){#F0004_20334}

###### 

Summary of treatment outcomes of MDR-TB patients in South Africa (n=13,692)

                                                              Treatment success                                                          
  -------------------------------------------- -------------- ------------------- ------------ -------------- ------------ ------------- --------------
  HIV status                                                                                                                             
  HIV −ve                                      3739 (27.3%)   803 (21.5%)         341 (9.1%)   460 (12.3%)    289 (7.7%)   773 (20.7%)   1073 (28.7%)
  HIV +ve                                      7289 (53.2%)   1356 (18.6%)        576 (7.9%)   1243 (17.1%)   390 (5.4%)   985 (13.5%)   2739 (37.5%)
  Unknown                                      2664 (19.5%)   328 (12.3%)         184 (6.9%)   383 (14.4%)    118 (4.4%)   236 (8.9%)    1415 (53.1%)
  TB treatment history                                                                                                                   
  New                                          3250 (23.7%)   653 (20.1%)         291 (9.0%)   439 (13.5%)    164 (5.0%)   476 (14.6%)   1227 (37.8%)
  Relapse                                      2351 (17.2%)   436 (18.5%)         177 (7.5%)   328 (14.0%)    139 (5.9%)   331 (14.1%)   940 (40.0%)
  LTF[a](#TF0001_20335){ref-type="table-fn"}   1232 (9.0%)    132 (10.7%)         80 (6.5%)    274 (22.2%)    99 (8.1%)    286 (23.2%)   361 (29.3%)
  Failed 1^st^                                 3959 (28.9%)   735 (18.6%)         333 (8.4%)   567 (14.3%)    186 (4.7%)   485 (12.3%)   1653 (41.7%)
  Failed 2^nd^                                 2516 (18.4%)   495 (19.7%)         197 (7.8%)   415 (16.5%)    180 (7.2%)   352 (14.0%)   877 (34.8%)
  Other                                        384 (2.8%)     36 (9.3%)           23 (6.0%)    63 (16.4%)     29 (7.6%)    64 (16.7%)    169 (44.0%)

LTF lost to follow-up; 1^st^ first-line; 2^nd^ second-line.

![TB-related death among HIV-positive patients according to the number of active drugs used as part of empiric TB therapy.](JIAS-18-20336-g001){#F0005_20336}

![Comparison of TB treatment outcomes according to HIV status in 14 African Countries 2012 cohort.](JIAS-18-20337-g001){#F0006_20337}

###### 

Analysis of the cascade of TB/HIV care in 14 high TB/HIV burden African Countries, 2012 cohort

                                            Est. HIV-pos incident TB cases   \% of est. HIV-pos TB cases unreported   Notified TB cases   \% of TB cases with unreported HIV status   Notified TB cases with HIV-pos status   \% of HIV-pos TB cases not on ART
  ----------------------------------------- -------------------------------- ---------------------------------------- ------------------- ------------------------------------------- --------------------------------------- -----------------------------------
  14 high burden TB/HIV African countries   570,000                          46                                       695,580             11                                          306,398                                 42

![KM graph for 5274](JIAS-18-20481-g001){#F0032_20481}

![Treatment cost for FSW population.](JIAS-18-20339-g001){#F0007_20339}

###### 

Outcomes and costs of TasP expansion scenarios

  Population   Target incidence reduction in FSW in 15 years (%)   No ART expansion new cases in 15 years   No ART expansion US\$ costs in 15 years   TasP Scenario 1 new cases in 15 years   TasP Scenario 1 US\$ costs in 15 years   TasP Scenario 2 new cases in 15 years   TasP Scenario 2 US\$ costs in 15 years
  ------------ --------------------------------------------------- ---------------------------------------- ----------------------------------------- --------------------------------------- ---------------------------------------- --------------------------------------- ----------------------------------------
  FSW          50                                                  2816                                     \$1,240,560                               2003                                    \$911,016                                2000                                    \$1,025,737
  Clients      50                                                  4096                                     \$3,841,072                               2878                                    \$3,308,139                              2847                                    \$3,139,332
  Both         50                                                  6912                                     \$5,061,632                               4881                                    \$4,219,155                              4847                                    \$4,165,069
  FSW          70                                                  2816                                     \$1,240,560                               1620                                    \$863,324                                1605                                    \$1,093,578
  Clients      70                                                  4096                                     \$3,841,072                               2331                                    \$3,030,029                              2259                                    \$2,782,224
  Both         70                                                  6912                                     \$5,061,632                               3951                                    \$3,893,353                              3864                                    \$3,875,802
  FSW          90                                                  2816                                     \$1,240,560                               1118                                    \$777,438                                1074                                    \$1,107,593
  Clients      90                                                  4096                                     \$3,841,072                               1615                                    \$2,818,353                              1480                                    \$2,260,854
  Both         90                                                  6912                                     \$5,061,632                               2733                                    \$3,595,791                              2554                                    \$3,368,447

![ART outcomes for Option B+ patients.](JIAS-18-20341-g001){#F0008_20341}

###### 

Women\'s baseline characteristics

  Characteristics                        Historical data     Intensification
  -------------------------------------- ------------------- -------------------
  N                                      3965                88
  Age (IQR) -- years                     25.7 (22.5--29.7)   26.3 (22.3--33.0)
  CD4 (IQR) -- cells/mm^3^               380 (260--527)      368 (255--503)
  VL baseline (IQR) -- log10 copies/mL   4.0 (3.4--4.6)      4.3 (3.7--4.7)
  VL delivery (IQR) -- log10 copies/mL   3.2 (2.3--4.0)      2.2 (1.8--2.9)
  GA delivery (IQR) -- weeks             38.7 (37.9--39.7)   38.6 (38.0--39.3)
  C/section (%)                          (21%)               (36%)

![Intrapartum transmission posterior probabilities.](JIAS-18-20344-g001){#F0009_20344}

![Facility-level variation of average cost per service in two stages of the PMTCT cascade vs. scale.](JIAS-18-20485-g001){#F0033_20485}

###### 

HIV cases and contacts identified during investigation

                                   HIV-positive N (%)   HIV-negative N (%)   Total N (%)
  -------------------------------- -------------------- -------------------- -------------
  Overall                          153                  237                  390
  Male sex                         88 (58)              132 (56)             220 (56)
  Median age (range)               34 (18--57)          35 (13--75)          34 (13--75)
  HIV risk factor                                                            
  Sexual risk only                 2 (1)                36 (15)              38 (10)
  Needle-sharing risk only         65 (42)              87 (37)              152 (39)
  Sexual and needle-sharing risk   59 (39)              36 (15)              95 (24)
  Unknown                          27 (18)              78 (33)              105 (27)

![Maximum likelihood phylogenetic tree of (a) HIV-1 pol sequences and (b) HCV NS 5b sequences.](JIAS-18-20489-g001){#F0034_20489}

###### 

Abstract MOAC0305LB--Table 1

  Characteristic                                                                                                                        Study regimen daily (D), n=59   Study regimen time (T), n=60   Study regimen event (E), n=60   p
  ------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- ------------------------------ ------------------------------- ---------
  Number of sex events during study, excluding oral sex                                                                                 1083                            1311                           1502                            0.20
  \% total sex events with complete coverage (or for sex events with partial coverage % pre-sex only, % post-sex only)                  66 (24, 2)                      47 (30, 8)                     52 (29, 6)                      0.03
  Total number of required pills taken                                                                                                  5370                            1708                           1063                            \<0.001
  Total % PrEP adherence                                                                                                                65                              46                             41                              \<0.001
  \% Participants with neurologic side effects (e.g. headache, dizzy and lightheaded)                                                   24                              20                             18                              0.64
  \% Participants with gastrointestinal side effects (e.g. nausea, vomiting, diarrhoea, bloating, gas)                                  39                              18                             28                              0.51
  \% Participants with detectable tenofovir (TFV) (\>0.31 ng/mL) in plasma when reporting sex in last 7 days at 10 weeks, at 30 weeks   74, 61                          76, 56                         64, 50                          0.58
  Median plasma TFV concentration (ng/mL) in plasma when reporting sex in last 7 days at 10 weeks, at 30 weeks                          83, 31                          24, 11                         15, 1                           0.49
  \% achieving effective plasma TFV concentration (\>5 ng/mL) when reporting sex in last 7 days at 10 weeks, at 30 weeks                63, 56                          72, 50                         61, 39                          0.65

###### 

Results from Bangkok HPTN 067/ADAPT study (n=178)

  Characteristic                                                                                                                                   Daily (D)     Time-driven (T)   Event-driven (E)   Total        p value
  ------------------------------------------------------------------------------------------------------------------------------------------------ ------------- ----------------- ------------------ ------------ ----------
  N                                                                                                                                                60            59                59                 178          --
  Median age                                                                                                                                       31            28                31                 31           --
  Number of sex events over full study, not including oral sex                                                                                     1485          1337              1018               --           0.16
  \% total events fully covered                                                                                                                    85            84                74                 --           See text
  Total required tablets actually taken                                                                                                            8047          3272              1255               --           \<0.001
  Total tablets required                                                                                                                           9420          4121              1928               --           \<0.001
  Total % adherence                                                                                                                                85            79                65                 --           \<0.001
  \% detectable (\>9.1 fmol/million) in PBMCs when reporting sex in last 7 days (at 10 weeks of follow up; at 30 weeks of follow up)               100; 91.3     96.6; 94.7        93.3; 85.7         96.7; 91.1   0.54
  Median drug concentration in PBMCs (fmol/million cells) when reporting sex in last 7 days (at 10 weeks of follow up; at 30 weeks of follow up)   81.1; 102.0   35.3; 46.8        26.4; 32.9         45.5; 60.7   \<0.001

![WHO ARV Guidelines Adoption by region.](JIAS-18-20345-g001){#F0010_20345}

###### 

Country level cascades versus 90--90--90 target

  Country                              \% Diagnosed   \% On ART   \% Undetectable HIV-RNA   Country                     \% Diagnosed   \% On ART   \% Undetectable HIV-RNA
  ------------------------------------ -------------- ----------- ------------------------- --------------------------- -------------- ----------- -------------------------
  UNAIDS 90--90--90 targets for 2020   90             82          73                        Brazil (2013)               80             48          40
  Switzerland (2012)                   84             76          73                        Canada (BC) (2011)          71             51          35
  Australia (2013)                     86             66          62                        USA (2013)                  82             40          30
  United Kingdom (2013)                76             68          61                        Sub-Saharan Africa (2013)   45             39          29
  Denmark (2010)                       85             62          59                        Georgia (2012)              52             26          20
  The Netherlands (2013)               73             59          53                        Estonia (2013)              87             29          19
  France (2010)                        81             60          52                        Russia (2013)               49             11          9

![Major outcomes of early HAART programs at CCASAnet.](JIAS-18-20347-g001){#F0011_20347}

![Number of patients receiving care within an Adherence Club and the proportion of all ART patients in the Cape Metro health district receiving care within an Adherence Club, January 2011--December 2014.](JIAS-18-20540-g001){#F0035_20540}

![Eradication of HIV-1 DNA in latently infected cells. A. Treatment of latently infected T-lymphocytes with PMA and TSA activates viral gene expression and expression of GFP reporter in more than 93% of the cells. The presence of gRNAs (LTR A/B) and Cas9 dramatically prevented viral replication. B. Examination of DNA by PCR and direct sequencing verifies removal of integrated proviral DNA from chromosome 16.](JIAS-18-20355-g001){#F0012_20355}

###### 

Changes in proteinuria and tubular proteinuria

  Median % change baseline to Week 48             E/C/F/TAF   FTC/TDF+3rd agent   Significance
  ----------------------------------------------- ----------- ------------------- --------------
  Urine protein: creatinine (UPCR)                −18.5%      +9.4%               p\<0.001
  Urine albumin: creatinine (UACR)                −18.4%      +5.3%               p\<0.001
  Retinol binding protein: creatinine (RBP: CR)   −32.9%      +15.7%              p\<0.001
  Beta-2-microglobulin: creatinine (B2MG: CR)     −49.2%      +14.4%              p\<0.001

###### 

Week 24 Efficacy, including subgroup responses by screening RNA ≤ or \>100,000 c/mL

  Endpoint                                                                  DOR[†](#TF0001_20359){ref-type="table-fn"} (N=108)   EFV[†](#TF0001_20359){ref-type="table-fn"} (N=108)   Difference \[DOR-EFV\] (95% CI)
  ------------------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------
  HIV RNA\<40c/mL[††](#TF0002_20359){ref-type="table-fn"}                   72.2%                                                73.1%                                                −1.2 (−13.0, 10.5)
   screening RNA ≤100K[§](#TF0003_20359){ref-type="table-fn"} (n=66, 63)    83.3%                                                85.7%                                                −2.4 (−15.3, 10.6)
   screening RNA \>100K[§](#TF0003_20359){ref-type="table-fn"} (n=38, 38)   60.5%                                                65.8%                                                −5.3 (−26.4, 16.4)
  HIV RNA\<200c/mL[††](#TF0002_20359){ref-type="table-fn"}                  88.9%                                                87.0%                                                1.9 (−7.0, 11.0)
   screening RNA≤100K[§](#TF0003_20359){ref-type="table-fn"} (n=66, 63)     92.4%                                                92.1%                                                0.4 (−9.8, 10.8)
   screening RNA \>100K[§](#TF0003_20359){ref-type="table-fn"} (n=38, 38)   92.1%                                                94.7%                                                −2.6 (16.5, 10.7)
  Mean change in CD4 count[§](#TF0003_20359){ref-type="table-fn"}           154/mm^3^                                            146/mm^3^                                            8 (−37, 52)

with TDF/FTC.

Non-completer=Failure (NC=F) approach to missing data.

Observed Failure (OF) approach to missing data.

###### 

Week 24 Clinical Adverse Event (AE) Summary & Primary Safety Analysis (CNS AEs)

  Proportion of patients with:   DOR[†](#TF0004_20359){ref-type="table-fn"} (N=108)   EFV[†](#TF0004_20359){ref-type="table-fn"} (N=108)   Difference \[DOR-EFV\] (95% CI)
  ------------------------------ ---------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------
  One or more AEs                75.9%                                                84.3%                                                −83 (−19.1, 2.4)
  Drug-related AEs               27.8%                                                55.6%                                                −27.8 (−39.9, 14.8)
  Serious AE                     0.9%                                                 4.6%                                                 −3.7 (−9.6, 0.9)
  Serious drug-related AEs       0%                                                   0.9%                                                 −0.9 (−5.1, 2.5)
  Discontinued due to AEs        0.9%                                                 5.6%                                                 −4.6 (−10.8, 0.1)
  One or more CNS AEs            26.9%                                                46.3%                                                −19.4 (−31.7, 6.6)[\*](#TF0005_20359){ref-type="table-fn"}

with TDF/FTC.

Pre-specified safety hypothesis, p\<0.001.

###### 

Raltegravir levels in a treated newborn

  Day of life   Weight (kg)   Dose       mg/kg/dose   Trough (hours)   Trough level   Peak (hours)   Peak level   Adjusted
  ------------- ------------- ---------- ------------ ---------------- -------------- -------------- ------------ -----------------------
  6             3.115         5 mg BID   1.61         11.67            0.36           1.97           0.87         No
  9             3.220         5 mg BID   1.55         11.25            0.75           1.25           0.15         No
  20            3.565         5 mg BID   1.40         12               0.07           1.17           0.33         No
  27            3.835         5 mg BID   1.30         11               0.06           1.15           0.02         Increased to 6 mg BID
  40            4.275         6 mg BID   1.40         N/A              N/A            N/A            N/A          Stopped

###### 

Changes in HIV-1 RNA from baseline

                                                                    BMS-955176 (40 mg QD)+ATV (400 mg QD)   BMS-955176 (40 mg QD)+ATV (300 mg QD)+RTV (100 mg QD)   BMS-955176 (80 mg QD)+ATV (400 mg QD)   Tenofovir disoproxil fumarate (300 mg QD)+emtricitabine (200 mg QD) (fixed-dose combination)+ATV (300 mg QD)+RTV (100 mg QD)
  ----------------------------------------------------------------- --------------------------------------- ------------------------------------------------------- --------------------------------------- ------------------------------------------------------------------------------------------------------------------------------
  N                                                                 8                                       8                                                       8                                       4
  Maximum decline in HIV-1 RNA (log~10~ c/mL); median (min, max)    −1.86 (−1.49, −2.37)                    −2.20 (−1.24, −3.52)                                    −2.23 (−1.87, −2.68)                    −2.39 (−1.83, −3.04)
  Median decline in HIV-1 RNA (log~10~ c/mL) on Day 29 (min, max)   −1.66 (−1.19, −2.04)                    −1.99 (−1.04, −3.32)                                    −2.18 (−1.53, −2.68)                    −2.22 (−1.83, −2.84)

![Median change in HIV-1 RNA (log~10~ c/mL) over time.](JIAS-18-20544-g001){#F0036_20544}

###### 

Multiplicative median change in APRI per 5 years

  Analysis                 APRI score at cohort entry, median (IQR)   PI users (APRI units/5 years), Exp(β) (95% CI)[a](#TF0001_20361){ref-type="table-fn"}   NNRTI users (APRI unit/5 years), Exp(β) (95% CI)[a](#TF0001_20361){ref-type="table-fn"}
  ------------------------ ------------------------------------------ --------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  1\. Intention-to-treat   0.63 (0.39--1.30)                          1.16 (1.03, 1.30)                                                                       1.05 (0.90, 1.20)
  2\. Per protocol         0.60 (0.39--1.22)                          1.16 (1.00, 1.32)                                                                       1.07 (0.89, 1.24)
  3\. As treated           0.63 (0.39--1.30)                          1.13 (0.99, 1.27)                                                                       1.09 (0.93, 1.25)

Adjusted for baseline age, sex and time since HCV infection and updated alcohol use, CD4 cell count, viral load or virologic failure and number or type of previous regimens.

###### 

SVR12 by HIV regimen and overall

  Virologic response            TDF+FTC+EFV (N=160)   TDF+FTC+RAL (N=146)   TDF+FTC+RPV (N=29)   Overall (N=335)
  ----------------------------- --------------------- --------------------- -------------------- -----------------
  SVR12, n (%)                  151 (94)              141 (97)              28 (97)              320 (96)
  On-Treatment Failure, n (%)   1 (\<1)               0                     1 (3)                2 (\<1)
  Relapse, n (%)                8 (5)                 2 (1)                 0                    10 (3)
  Other, n (%)                  0                     3 (2)                 0                    3 (\<1)

###### 

SVR12 rates by baseline characteristic, n/N (%)

  --------------------------------------------------------------------------------------------------------
  Characteristic                           12-week OBV/PTV/r + DSV + RBV   24-week OBV/PTV/r + DSV + RBV
  ---------------------------------------- ------------------------------- -------------------------------
  Overall                                  29/31 (94)                      29/32 (91)

  Black race\                              7/7 (100)\                      7/8 (88)\
   Hispanic or Latino ethnicity            7/8 (88)                        7/8 (88)

  Age, ≥55 years                           7/8 (88)                        12/12 (100)

  BMI ≥30                                  3/3 (100)                       7/7 (100)

  IL28B genotype\                          \                               \
   CT\                                     16/16 (100)\                    19/20 (95)\
   TT                                      8/10 (80)                       4/5 (80)

  Prior pegIFN/RBV treatment experience\   \                               \
   Naïve\                                  \                               \
   Relapser\                               19/20 (95)\                     20/22 (91)\
   Partial response\                       1/1 (100)\                      3/3 (100)\
   Null response                           5/5 (100)\                      2/2 (100)\
                                           4/5 (80)                        4/5 (80)

  Baseline HCV RNA\                        25/27 (93)\                     26/28 (93)\
   ≥800,000 IU/mL\                         \                               \
   Baseline CD4+ T-cell\                   2/2 (100)\                      5/5 (100)\
   cells/mm^3^\                            8/8 (100)                       7/8 (88)
   \<350\                                                                  
   350 -- \<500                                                            

  Baseline CD4+ T-cells/mm^3^\             \                               \
   \<350\                                  \                               \
   350 -- \<500\                           2/2 (100)\                      5/5 (100)\
  Baseline fibrosis stage\                 8/8 (100)\                      7/8 (88)\
   F2\                                     \                               \
   F3\                                     5/5 (100)\                      5/5 (100)\
   F4                                      3/4 (75)\                       1/1 (100)\
                                           5/6 (83)                        5/6 (83)
  --------------------------------------------------------------------------------------------------------

SVR12, sustained virologic response at post-treatment week 12; OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; DSV, dasabuvir; RBV, ribavirin.

###### 

Abstract TUAB0204--Table 1

                                          SVR (42)         No SVR (91)                                                           
  --------------------------------------- ---------------- ------------------- ---------- ------------------ ------------------- ------------
  TE (Kpa)                                7.1 (6.3--8.8)   17.5 (13.8--26.3)   \<0.01     11.6 (6.3--11.2)   21.3 (17.2--45.4)   \<0.01
  Death (n, %) IR                         4 (17%) 2.45     6 (32%) 5.36        0.01       2 (14%) 1.3        37 (48%) 7.6        \<0.01
  Liver-related death (n, %), IR          1 (4%) 0.61      3 (16%) 2.68        0.01       1 (7%) 3.65        29 (38%) 5.9        \<0.01
  Liver-related complications (n, %) IR   1 (4%) 1.22      2 (11%) 1.78        0.2 0.15   5 (36%) 3.25       33 (43%) 6.81       0.01\<0.01
  Hospital admissions (n, %) IR           2 (9%) 1.22      3 (16%) 2.68        0.7 0.13   4 (29%) 2.6        27 (30%) 5.6        0.2 0.04

###### 

Inclusion/exclusion criteria

  Exclusion criteria (exclusive)                                  No (%) among genotype 1 (n=699)   No (%) among genotypes 1, 2 and 3 (n=887)
  --------------------------------------------------------------- --------------------------------- -------------------------------------------
  Specific cART regimens[a](#TF0001_20365){ref-type="table-fn"}   380 (54)                          484 (55)
  Active drug abuse within 12 months (excluding marijuana use)    320 (46)                          402 (45)
  HIV VL\>50 copies/mL                                            175 (25)                          225 (25)
  HbA1c\>10% (used HOMA IR\>2 as surrogate)                       171 (24)                          217 (24)
  APRI[b](#TF0002_20365){ref-type="table-fn"} of \<1 or ≥2        129 (18)                          171 (19)
  CD4 T-cell count \<200 cells/mm^3^                              106 (15)                          136 (15)
  Decompensated liver disease                                     23 (3)                            27 (3)

SOF trial: emtricitabine/tenofovir plus atazanavir/ritonavir; or darunavir/ritonavir; efavirenz; raltegravir; rilpivirine. SIM trial: excluded all boosted PIs and allowed only raltegravir, sustiva and ripilvirine;

aspartate aminotransferase/platelet ratio index (APRI) \<1 defined as non-cirrhotic or ≥2 defined as cirrhotic based on SOF trial.

###### 

SVR12 by genotype

                                                                       All patients   GT1a         GT1b         GT4
  -------------------------------------------------------------------- -------------- ------------ ------------ ------------
  **SVR12[b](#TF0002_20545){ref-type="table-fn"}**                                                              
  n/N                                                                  207/218        136/144      42/44        27/28
  \%                                                                   95.0%          94.4%        95.5%        96.4%
  95% CI                                                               91.2, 97.5     89.3, 97.6   84.5, 99.4   81.7. 99.9
                                                                                                                
  **LTFU or unrelated to VF[c](#TF0003_20545){ref-type="table-fn"}**   4              3            1            0
  Relapse[d](#TF0004_20545){ref-type="table-fn"}                       5              4            0            1
  Reinfection                                                          2              1            1            0

FAS (Full Analysis Set): all patients who received at least one dose of GZR/EBR.

HCV RNA assessed via COBAS TaqMan v2.0 \[lower limit of quantitation \<15 IU/mL\].

N=Number of subjects included in the analysis.

n (%)=Number of subjects who achieved SVR12 and the percentage calculated as (n/N)\*100.

Two subjects were lost to follow-up; one patient was discontinued for taking a prohibited concomitant medication, and one subject\'s FW12 visit was outside the analysis window.

At baseline in the NSSA gene, one of the relapses had L31M/L RAV and one of the relapses had the Y93S RAV. The other three relapses had the WT NSSA gene at baseline.

###### 

Efficacy of DCV+SOF±RBV regimens in HIV/HCV co-infection

  Treatment duration   Genotype status                                                                                                       
  -------------------- ----------------- ----------------- ----------------- --------------- --------------- --------------- --------------- ---------------
  SVR4, N=164          41/49 (83.7%)     107/115 (93.0%)   104/116 (89.7%)   80/87 (92.0%)   13/15 (86.7%)   12/13 (92.3%)   26/28 (92.9%)   16/17 (94.1%)
  SVR12, N=98          30/31 (96.8%)     64/67 (95.5%)     66/68 (97.1%)     52/53 (98.1%)   11/11 (100%)    11/11 (100%)    14/15 (93.3%)   10/11 (90.9%)

![Adherence, Risk Behavior and STI incidence Over Time in the Demo Project.](JIAS-18-20371-g001){#F0013_20371}

![Tenofovir diphosphate levels (fmol/punch) and PrEP dosing estimates as measured by dried blood spot assay.](JIAS-18-20549-g001){#F0037_20549}

###### 

Study population characteristics and PrEP uptake

                                                            Approached ([1](#TF0001_20550){ref-type="table-fn"}) N (%)   Potentially Eligible ([2](#TF0002_20550){ref-type="table-fn"}) N (%)   Included ([3](#TF0003_20550){ref-type="table-fn"}) N (%)   Declined ([4](#TF0004_20550){ref-type="table-fn"}) N (%)   Percent of PrEP uptake[\*](#TF0006_20550){ref-type="table-fn"}   p-value[\*\*](#TF0007_20550){ref-type="table-fn"}
  --------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------
  Overall                                                   986                                                          798                                                                    409                                                        365                                                        51.25                                                            
  Site location ([5](#TF0005_20550){ref-type="table-fn"})                                                                                                                                                                                                                                                                                                                              \<0.001
   FIOCRUZ                                                  622 (63.08)                                                  455 (57.02)                                                            175 (42.79)                                                282 (77.26)                                                38.46                                                            
   CRT-SP                                                   225 (22.82)                                                  216 (27.07)                                                            135 (33.01)                                                57 (15.62)                                                 62.5                                                             
   USP-SP                                                   139 (14.1)                                                   127 (15.91)                                                            99 (24.21)                                                 26 (7.12)                                                  77.95                                                            
  Age years                                                                                                                                                                                                                                                                                                                                                                            0.26
   18--25                                                   335 (33.98)                                                  266 (33.33)                                                            127 (31.05)                                                128 (35.07)                                                47.74                                                            
   26--35                                                   435 (44.12)                                                  358 (44.86)                                                            189 (46.21)                                                165 (45.21)                                                52.79                                                            
   36--45                                                   160 (16.23)                                                  124 (15.54)                                                            62 (15.16)                                                 57 (15.62)                                                 50                                                               
   \>45                                                     56 (5.68)                                                    50 (6.27)                                                              31 (7.58)                                                  15 (4.11)                                                  62                                                               
  Sexual Identity                                                                                                                                                                                                                                                                                                                                                                      0.04
   Homosexual                                               823 (83.55)                                                  658 (82.56)                                                            343 (83.86)                                                293 (80.49)                                                52.13                                                            
   Bisexual                                                 99 (10.05)                                                   87 (10.92)                                                             36 (8.8)                                                   47 (12.91)                                                 41.38                                                            
   Tranagender woman                                        44 (4.47)                                                    36 (4.52)                                                              24 (5.87)                                                  14 (3.85)                                                  66.67                                                            
   Other                                                    19 (1.93)                                                    16 (2.01)                                                              6 (1.47)                                                   10 (2.75)                                                  37.5                                                             
  Color/Race                                                                                                                                                                                                                                                                                                                                                                           0.05
   White                                                    455 (46.15)                                                  399 (50)                                                               219 (53.55)                                                161 (44.11)                                                54.89                                                            
   Non-white                                                531 (53.85)                                                  399 (50)                                                               190 (46.45)                                                204 (55.89)                                                47.62                                                            
  Schoolong years                                                                                                                                                                                                                                                                                                                                                                      0.06
   \<12                                                     89 (9.03)                                                    66 (8.27)                                                              26 (6.36)                                                  42 (11.51)                                                 39.39                                                            
   \>12                                                     897 (90.97)                                                  732 (91.73)                                                            383 (93.64)                                                323 (88.49)                                                52.32                                                            
  Steady partner                                                                                                                                                                                                                                                                                                                                                                       \<0.001
   Yes                                                      472 (47.87)                                                  385 (48.25)                                                            223 (54.52)                                                149 (40.82)                                                57.92                                                            
   No                                                       514 (52.13)                                                  413 (51.75)                                                            186 (45.48)                                                216 (59.18)                                                45.04                                                            
  Perceived likelihood of getting HIV in the next year                                                                                                                                                                                                                                                                                                                                 \<0.001
   0--25%                                                   569 (57.71)                                                  437 (54.76)                                                            189 (46.21)                                                237 (64.93)                                                43.25                                                            
   50--100%                                                 417 (42.29)                                                  361 (45.24)                                                            220 (53.79)                                                128 (35.07)                                                60.94                                                            
  Previous HIV test (last 12 months)                                                                                                                                                                                                                                                                                                                                                   \<0.001
   Yes                                                      657 (66.63)                                                  575 (72.06)                                                            334 (81.66)                                                219 (60)                                                   58.09                                                            
   No                                                       329 (33.37)                                                  223 (27.94)                                                            75 (18.34)                                                 146 (40)                                                   33.63                                                            
  Prior PrEP awareness                                                                                                                                                                                                                                                                                                                                                                 \<0.001
   Yes                                                      594 (60.43)                                                  498 (62.64)                                                            296 (72.55)                                                183 (50.41)                                                59.44                                                            
   No                                                       389 (39.57)                                                  297 (37.36)                                                            112 (27.45)                                                180 (49.59)                                                37.71                                                            
  \# Male condomless anal sex partners (last 12 months)                                                                                                                                                                                                                                                                                                                                \<0.001
   \<2                                                      512 (51.93)                                                  370 (46.37)                                                            143 (34.96)                                                222 (60.82)                                                38.65                                                            
   2 or more                                                474 (48.07)                                                  428 (53.63)                                                            266 (65.04)                                                143 (39.18)                                                62.15                                                            
  Anal sex with HIV-positive partners (12 months)                                                                                                                                                                                                                                                                                                                                      \<0.001
   Yes                                                      346 (35.09)                                                  324 (40.6)                                                             208 (50.86)                                                104 (28.49)                                                64.2                                                             
   No                                                       211 (21.4)                                                   87 (10.9)                                                              41 (10.02)                                                 44 (12.05)                                                 47.13                                                            
  I do not know                                             429 (43.51)                                                  387 (48.5)                                                             160 (39.12)                                                217 (59.45)                                                41.34                                                            
  STD diagnosis (12 months)                                                                                                                                                                                                                                                                                                                                                            0.01
   Yes                                                      138 (14)                                                     128 (16.04)                                                            79 (19.32)                                                 39 (10.68)                                                 61.72                                                            
   No                                                       848 (86)                                                     670 (83.96)                                                            330 (80.68)                                                326 (89.32)                                                49.25                                                            

All individuals approached for pre-screening who were age 18 or older, male at birth, lived in the State, self-reported HIV negative status and reported having at least one male sexual partner in last 12 months.

Includes all individuals approached at pre-screening (1) who: a) reported 2 or more male condomless anal sex partners OR anal sex with HIV positive partner OR STD diagnosis in last 12 months; and b) had a negative HIV test results.

Individuals who enrolled the study.

Decline represents the sum of refusals in all steps. Indivuduals who agreed to participate but did not show up at the screen or enrollment visit were considered as declining.

FIOCRUZ-RJ: Fundação Oswaldo Cruz, located in Rio de Janelro; CRT-SP: Centro de Referencla e Treinamento em DST e AIDS, located in São Paulo; USP-SP: Universidade de São Paulo.

\% uptake- \# Included/\# Potentially elligible at pre-screening.

chi-square for bivariate analyses.

###### 

Compartmental pharmacokinetics of tenofovir gel

                     Vaginal use phase   Rectal use phase                                                 
  ------------------ ------------------- ------------------ ----------------- ------------- ------------- -----------------
  Plasma                                                                                                  
  TFV (ng/mL)        0.99 (1.27)         10/14 (71%)        0.58 (0, 1.31)    1.19 (1.74)   10/14 (71%)   0.82 (0, 1.22)
  Vaginal tissue                                                                                          
  TVF (ng/mg)        45.8 (72.6)         12/13 (92%)        8.5 (1.0, 44.8)   0.09 (0.12)   6/14 (43%)    0 (0, 0.16)
  TFV-DP (fmol/mg)   1945 (4105)         12/13 (92%)        166 (37, 2377)    13 (30)       3/14 (21%)    0 (0, 0)
  Rectal tissue                                                                                           
  TFV (ng/mL)        0.02 (0.06)         1/13 (8%)          0 (0, 0)          12.2 (27.1)   12/14 (86%)   3.0 (0.7, 10.9)
  TFV-DP (fmol/mg)   10.48 (25.81)       2/13 (15%)         0 (0,0)           710 (1306)    10/14 (71%)   196 (0, 550)

![Proportion of HIV repeat testers.](JIAS-18-20374-g001){#F0014_20374}

![Cumulative risk of acquiring HIV among MSM.](JIAS-18-20375-g001){#F0015_20375}

###### 

Proportion of MSM sampled who had anal sex \<18 yr

  Country                        Percentage (n/N) of MSM study participants who first had anal sex with a man when they were under the age of 18   Percentage of study participants under 18 years old
  ------------------------------ ----------------------------------------------------------------------------------------------------------------- -----------------------------------------------------
  Bobo-Dioulasso, Burkina Faso   51.21% (169/330)                                                                                                  N/A
  Ouagadougou, Burkina Faso      51.31% (176/343)                                                                                                  N/A
  Kara, Togo                     41.95% (138/329)                                                                                                  N/A
  Lome, Togo                     63.84% (226/354)                                                                                                  N/A
  Gambia                         43.69% (90/206)                                                                                                   12.14% (25/206)
  Maputsoe, Lesotho              40.95% (129/315)                                                                                                  N/A
  Maseru, Lesotho                35.85% (76/212)                                                                                                   N/A
  Malawi                         16.32% (55/337)                                                                                                   N/A
  Swaziland                      14.46% (47/325)                                                                                                   N/A

###### 

Baseline characteristics of HIV-positive and HIV-negative

                                                            Total (n=242)   Australia (n=137)   Brazil (n=53)   Thailand (n=52)
  --------------------------------------------------------- --------------- ------------------- --------------- -----------------
  HPP: taking ART                                           194 (80.2)      124 (90.5)          45 (84.9)       25 (48.1)
  HPP: viral load \<200 copies/mL (available for 227 HPP)   189 (83.3)      119 (88.2)          34 (85.0)       36 (69.2)
  HPP: Adherence to ART \>90% (of those taking ART)         170 (91.9)      107 (92.2)          40 (88.9)       23 (95.8)
  HNP: perceived VL of HPP                                                                                       
  Undetectable VL                                           148 (61.2)      107 (78.1)          34 (64.2)       7 (13.5)
  Detectable VL                                             58 (24.0)       23 (16.8)           10 (18.9)       25 (48.1)
  Don\'t know VL                                            36 (14.9)       7 (5.1)             9 (17.0)        20 (38.5)
  HNP: any CLAI with outside partners, last three months    45 (18.6)       38 (27.7)           2 (3.8)         5 (9.6)
  HNP: any CLAI with study partner, last three months       132 (54.6)      93 (67.9)           24 (45.3)       15 (28.9)

![(a) Population size estimation using four independent methods, Maputio City. (b) Population size estimation using four independent methods, Nampula.](JIAS-18-20379-g001){#F0016_20379}

![Retention on ART and viral suppression among PWID enrolled in the study disaggregated by CD4 at ART initiation.](JIAS-18-20382-g001){#F0017_20382}

###### 

Abstract TUAC0406LB--Table 1

  Scenario                                                        Average time before linkage to care (years)   Prevalence after 10 years (%) mean (95% CI)   Incidence after 10 years (/100 persons-years) mean (95% CI)   \% of compilation avoided compared to Scenario 1 over 40 years mean (95% CI)
  --------------------------------------------------------------- --------------------------------------------- --------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------
  Scenario 1 (Reference)                                                                                                                                                                                                    
  New DAAs under the current cascade of care:                     1                                             54.6 (54.4;54.8)                              9.4 (9.1;9.6)                                                 /
  average time from chronic infection to diagnosis δ=2.0 years;   3                                             57.7 (57.5;57.8)                              10.1 (9.8;10.4)                                               /
  annual lost to follow-up probability Ψ=14%;                     5                                             59.5 (59.4;59.7)                              10.3 (10;10.6)                                                /
  initiation of treatment if linked to care α=5%/year;                                                                                                                                                                      
  SVR rate with current adherence to treatment                                                                                                                                                                              
  (SVR)=81.3%                                                                                                                                                                                                               
  Scenario 2                                                      1                                             53.5 (53.3;53.7)                              9.1 (8.9;9.4)                                                 0.9 (−0.2;2.0)
  Decrease time from chronic infection to diagnosis:              3                                             56.8 (56.7;57)                                9.9 (9.6;10.1)                                                1.7 (0.8;2.6)
  δ=0.5 years                                                     5                                             58.7 (58.5;58.9)                              10.1 (9.9;10.4)                                               1.7 (0.7;2.7)
  Scenario 3                                                      1                                             53.3 (53.1;53.5)                              9.1 (8.8;9.4)                                                 2.7 (1.6;3.8)
  Improve adherence to treatment:                                 3                                             56.6 (56.5;56.8)                              9.6 (9.4;9.9)                                                 3.2 (2.2;4.2)
  SVR rate likewise in clinical trials (SVR=90%)                  5                                             58.5 (58.3;58.7)                              9.8 (9.5;10.1)                                                3.4 (2.6;4.3)
  Scenario 4                                                      1                                             45.6 (45.4;45.8)                              7.8 (7 6;8.0)                                                 15.5 (14.7;16.3)
  Improve treatment rate:                                         3                                             50.5 (50.3;50.7)                              8.4 (8.2;8.7)                                                 14.6 (13.7;15.4)
  α=10%/year                                                      5                                             53.5 (53.4;53.7)                              9.1 (8.9;9.4)                                                 12.4 (11.5;13.2)
  Scenario 5                                                      1                                             34.1 (33.9;34.3)                              6.1 (5.9;6.3)                                                 29.6 (28.9;30.2)
  Improve treatment rate:                                         3                                             41.4 (41.2;41.6)                              7.3 (7.1;7.5)                                                 27.2 (26.3;28.0)
  α=20%/year                                                      5                                             45.7 (45.5;45.9)                              7.8 (7.6;8.1)                                                 24.3 (23.6;25.1)
  Scenario 6                                                      1                                             26.9 (26.7;27.0)                              4.9 (4.8;5.1)                                                 39.3 (38.8;39.8)
  Combined scenario                                               3                                             35.7 (35.5;35.8)                              6.4 (6.2;6.6)                                                 34.8 (34.2;35.4)
  combine scenarios 2, 3 and 5                                    5                                             41.2 (41;41.4)                                7.2 (7.1;7.4)                                                 31.6 (30.8;32.4)

CI: confidence interval

SVR: Sustained virological response

![HIV mortality along the care cascade.](JIAS-18-20384-g001){#F0018_20384}

![Area under ROC curve with 95% CI (private programme).](JIAS-18-20385-g001){#F0019_20385}

###### 

Pre-specified sub-analyses among MSM in China

                              Crowdsourced      Health marketing                                                                
  --------------------------- ----------------- ------------------ ------------ --------- ----------------- ------ ------------ -------
  Multi-time video watching   66/126 (52.4%)    1.97               1.47--2.65   \<0.001   67/151 (44.4%)    1.67   1.23--2.28   0.001
  First-time video watching   48/181 (26.5%)    Ref                                       44/166 (26.5%)    Ref                 
  Northern web portal         106/316 (33.5%)   1.27               0.70--2.33   0.42      90/266 (26.6%)    0.82   0.57--1.88   0.30
  Other web portals           8/36 (22.2%)      Ref                                       21/51 (41.2%)     Ref                 
  Yes -- condomless sex       28/71 (39.4%)     1.21               0.84--1.74   0.62      26/62 (41.9%)     1.30   0.90--1.88   0.16
  No -- condomless sex        50/153 (32.7%)    Ref                                       52/161 (32.3%)    Ref                 
  Overall                     114/307 (37.1%)                                             111/317 (35.0%)                       

![Flowchart of programme implementation.](JIAS-18-20553-g001){#F0038_20553}

###### 

Summary of intention-to-treat (ITT) and modified I

  Population, outcome                            \% Achieved by end of observation period   Hazard ratio (95% CI) of incidence rates in intervention versus control period
  ---------------------------------------------- ------------------------------------------ --------------------------------------------------------------------------------
  Total population, viral suppression                                                       
  ITT analysis (N=1008)                          30                                         1.27 (0.89--1.80)
  mITT analysis (N=824)                          37                                         1.18 (0.83--1.68)
  No labs for 12 months, relinkage                                                          
  mITT analysis (N=276)                          47                                         0.99 (0.74--1.34)
  No labs for 12 months, viral suppression                                                  
  mITT analysis (N=276)                          28                                         0.79 (0.40--1.55)
  Last VL\>500 in past year, viral suppression                                              
  mITT analysis (N=548)                          41                                         1.4 (0.96--2.19)

###### 

Comparison of PMTCT outcomes

  Outcome indicator                                                                                           Average effects among matched exposed subjects in m2m sites (%)   Average effects among matched unexposed subjects in control sites (%)   PSM net effect (percentage points)   p
  ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------ ---------
  Receipt of ARVs/ART for PMTCT among HIV-positive pregnant women                                             91.8                                                              95.1                                                                    −3.3                                 \<0.001
  ANC attendance at least four times during pregnancy among HIV-positive women                                49.30                                                             39.70                                                                   9.6                                  \<0.001
  Delivery by skilled health personnel in past 12 months among HIV-positive women                             87.10                                                             75.80                                                                   11.3                                 \<0.001
  Retention in care among HIV-positive women 12 months after ART initiation                                   90.90                                                             63.60                                                                   27.3                                 \<0.001
  Receipt of Nevirapine suspension at birth by HIV-exposed babies (ART prophylaxis for PMTCT)                 86.00                                                             59.00                                                                   27                                   \<0.001
  Percentage of HIV-exposed children who were given a PCR test at six weeks after birth                       71.50                                                             45.80                                                                   25.8                                 \<0.001
  Percentage of HIV-exposed children who were given an HIV test six weeks after cessation of breast feeding   60.50                                                             31.40                                                                   29.4                                 \<0.001
  Percentage of HIV-exposed children who were given an HIV test 18 months after delivery                      60.20                                                             18.10                                                                   42.1                                 \<0.001
  Linkage of HIV-positive babies to paediatric ART                                                            60.90                                                             27.80                                                                   33                                   \<0.001

![Participants tree.](JIAS-18-20389-g001){#F0020_20389}

###### 

Effect of conditional cash compensation

                                                          Study group   Odds ratio (95% CI)                                                                  
  ------------------------------------------------------- ------------- --------------------- ------------- ------------------- -------- ------------------- --------
  Loss to follow-up                                                                                                                                          
   Yes                                                    91 (22.36)    36 (17.73)            55 (26.96)    0.58 (0.36, 0.94)   0.0255   0.58 (0.36, 0.93)   0.0235
   No                                                     316 (77.64)   167 (82.27)           149 (73.04)                                                    
  Attendance of each clinic visit and received services                                                                                                      
   Yes                                                    254 (63.41)   142 (69.95)           112 (54.90)   1.91 (1.27, 2.87)   0.0017   1.97 (1.30, 2.97)   0.0013
   No                                                     153 (37.59)   61 (30.05)            92 (45.10)                                                     

![PMTCT critical path.](JIAS-18-20390-g001){#F0021_20390}

![Proportion of patients on ART Option B+ retained six months after treatment.](JIAS-18-20392-g001){#F0022_20392}

###### 

Change in gestational age at first antenatal care

  Gestational age at first ANC   Baseline July--September 2013 (January--March 2014, Uganda) n=5071   6--12 months of implementation October--December, 2014 n=4799   p-value
  ------------------------------ -------------------------------------------------------------------- --------------------------------------------------------------- -----------
  ≤20 weeks                      1532 (30.2%)                                                         1975 (41.2%)                                                    p\<0.0001
  21+weeks                       3539 (69.8%)                                                         2824 (58.8%)                                                    

###### 

Broad/potent neutralization and target recognized

  Category                       Less potent (geo mean ID50\<220)   Potently neutralizing (geo mean ID50\>220)   Relative risk (95% CI)   p (X^2^)   Less broad (neutralizes\<18/24 viruses)   Broadly neutralizing (neutralizes≥18/24 viruses)   Relative risk (95% CI)   p (X^2^)
  ------------------------------ ---------------------------------- -------------------------------------------- ------------------------ ---------- ----------------------------------------- -------------------------------------------------- ------------------------ ----------
  Anti-MPER negative             124                                20                                           1.00 (reference)                    122                                       22                                                 1.00 (reference)         
  Anti-MPER positive             24                                 9                                            1.96 (0.99, 3.91)        0.061      23                                        10                                                 1.98 (1.04, 3.78)        0.043
  Anti-V2 glycan site negative   63                                 21                                           1.00 (reference)                    62                                        22                                                 1.00 (reference)         
  Anti-V2 glycan site positive   29                                 5                                            0.59 (0.24, 1.43)        0.222      27                                        7                                                  0.79 (0.37, 1.67)        0.522
  Anti V3/glycans negative       75                                 17                                           1.00 (reference)                    73                                        19                                                 1.00 (reference)         
  Anti-V3/glycans positive       12                                 9                                            2.32 (1.21, 4.46)        0.017      12                                        9                                                  2.08 (1.10, 3.92)        0.033

![Total HIV-1 DNA (a) and integrated HIV-1 DNA (b) levels in four patient cohorts. Data is shown as log10 copies/million (c/M) PBMC and significant p-values are indicated by \*. Differences between the cohorts were determined by Wilcoxon Signed Rank test.](JIAS-18-20398-g001){#F0023_20398}

![Plasma viral load by 2G EIA reactivity.](JIAS-18-20399-g001){#F0024_20399}

###### 

Non-reactivity to enzyme immunoassay

  Non-reactivity to HIV enzyme immunoassay, N (%)                                                                
  ------------------------------------------------- ----------- ------------------------------------------------ ------------------------------------------------
  2nd generation EIA                                207 (100)   51 (34)[a](#TF0001_20399){ref-type="table-fn"}   53 (39)[a](#TF0001_20399){ref-type="table-fn"}
  3rd generation EIA                                99 (48)     5 (3)[a](#TF0001_20399){ref-type="table-fn"}     7 (5)[a](#TF0001_20399){ref-type="table-fn"}
  4th generation IA                                 43 (21)     30 (20)                                          24 (18)

McNemar\'s test, p\<0.001, compared to baseline (Note: no significant difference between week 12 and 24).

###### 

Transmitted drug resistance among MSM in Bangkok

                       Total      2009--2010   2011--2012   2013--2014   
  -------------------- ---------- ------------ ------------ ------------ ------
  N enrolled           184        32           52           100          
  Any resistance       13 (7.1)   4 (12.5)     5 (9.6)      4 (4.0)      0.07
  N with RT genotype   183        32           51           100          
  NRTI mutations       6 (3.3)    2 (6.3)      2 (3.9)      2 (2.0)      0.23
  NNRTI mutations      4 (2.2)    3 (9.4)      1 (2.0)      0 (0)        0.03
  N with PR genotype   180        32           50           98           
  PI mutations         6 (3.3)    1 (3.1)      3 (6.0)      2 (2.0)      0.52

###### 

Predictors of HIV -- South African Health Monitoring Study, 2014, and current ART utilization

                                                  Johannesburg   Cape Town    Durban                         
  ----------------------------------------------- -------------- ------------ -------- ------------- ------- --------------
  Venue of sex work (street based is reference)                                                              
   Brothel based only                             0.59           0.35--0.99   2.13     1.46--3.12    2.31    1.37--3.89
   Street and brothel based only                  3.01           1.15--7.89   0.01     0.0--149.77   0.18    0.02--1.69
  Health care utilization                         1.35           1.16--1.56   --       --            1.26    1.13--1.41
  ANC utilization                                 0.28           0.17--0.47   1.63     1.10--2.43    1.8     1.07--3.03
  Peer education exposure                         3.1            1.88--5.12   0.31     0.19--0.51    --      --
  UAI with non-paying partner                     --             --           --       --            28.55   10.52--77.56
  Age                                             1.13           1.08--1.18   --       --            1.19    1.15--1.24

![](JIAS-18-20404-g001){#F0025_20404}

![Engagement of South African FSW in the HIV care cascade.](JIAS-18-20556-g001){#F0039_20556}

###### 

Predictors of ART use among ART-eligible FSW

                                                                                Prevalence ratio \[95% CI\]   p-value   Adjusted prevalence ratio \[95% CI\][†](#TF0001_20556){ref-type="table-fn"}   p-value
  -------------------------------- -------------------------------------------- ----------------------------- --------- ----------------------------------------------------------------------------- ---------
  Age (REF≥30 years)               18--29 years                                 0.78 \[0.60--1.02\]           0.069     0.87 \[0.66--1.16\]                                                           0.346
  Number of clients past 30 days   0--10                                        REF                           0.074     REF                                                                           
                                   11 or more                                   1.24 \[0.98--1.57\]           0.074     1.29 \[1.02--1.63\]                                                           0.032
  Partnership and disclosure       No non-paying intimate partner               REF                           --        REF                                                                           --
                                   Disclosed to some or all intimate partners   0.87 \[0.69--1.09\]           0.219     0.86 \[0.69--1.08\]                                                           0.188
                                   Has not disclosed to intimate partners       0.41 \[0.19--0.87\]           0.021     0.47 \[0.23--0.95\]                                                           0.036
  Mother                           No                                           REF                                     REF                                                                            
                                   Yes                                          0.82 \[0.62--1.08\]           0.156     0.76 \[0.58--0.99\]                                                           0.047

Univariate analyses also assessed age, race, education, mobility, violence and depression. The adjusted model includes variables statistically significant at p\<0.20 in univariate analyses, including variables listed, age and time since HIV diagnosis.

![Kaplan-Meier plots over the first 18-months in a Community-based Adherance Club: (a) LTFU by gender, (b) LFTU by age, (c) Viral rebound by gender, (d) Viral rebound by age.](JIAS-18-20407-g001){#F0026_20407}

###### 

Person-years contributed and characteristics

  Characteristic             Not Retained^a^     Retained^a^         p\*      Not on cART^b^      On cART^b^          p\*      Not virally suppressed^c^   Virally suppressed^c^   p\*
  -------------------------- ------------------- ------------------- -------- ------------------- ------------------- -------- --------------------------- ----------------------- --------
  Total                      22,386              67,171              \<0.01   11,565              57,312              \<0.01   19,369                      41,271                  \<0.01
  Age (years)                33.9 (28.2, 40.6)   36.4 (30.0, 43.9)   \<0.01   32.5 (27.1, 39.3)   35.5 (29.6, 42.4)   \<0.01   33.5 (27.7, 40.4)           36.0 (30.1, 42.9)       \<0.01
  Male sex                   14,238 (25.1)       42,487 (74.9)       0.35     8119 (16.5)         40,982 (83.5)       \<0.01   13,493 (31.0)               29,981 (69.0)           \<0.01
  Female sex                 8148 (24.8)         24,684 (75.2)                3446 (17.4)         16,330 (82.6)                5876 (34.2)                 11,290 (65.8)            
  MSM HIV risk               7050 (27.6)         18,503 (72.4)       \<0.01   5079 (18.6)         22,225 (81.4)       \<0.01   7537 (31.4)                 16,489 (68.6)           \<0.01
  IDU HIV risk               820 (52.7)          735 (47.3)                   203 (15.1)          1141 (84.9)                  349 (29.3)                  842 (70.7)               
  Hetero HIV risk            8443 (29.2)         20,495 (70.8)                4800 (16.1)         24,945 (83.9)                8921 (34.4)                 17,044 (65.6)            
  Other/unk. HIV risk        6073 (18.1)         27,438 (81.9)                1483 (14.2)         9001 (85.9)                  2562 (27.1)                 6896 (72.9)              
  Individual years in care   7 (4, 9)            7 (4, 9)            \<0.01   6 (3, 8)            8 (5, 10)           \<0.01   6 (4, 9)                    8 (5, 10)               \<0.01

![Figure in HIV care continuum outcomes in CCASAnet.](JIAS-18-20410-g001){#F0027_20410}

![Viral suppression over time by ART initiation strategy.](JIAS-18-20557-g001){#F0040_20557}

![Active referral increases paediatric HIV testing.](JIAS-18-20411-g001){#F0028_20411}

![Children 0--14 years newly initiated on Antiretroviral therapy (July 2013 to June 2014).](JIAS-18-20413-g001){#F0029_20413}

![(a) Optimized spending to minimize HIV incidence and AIDS-related deaths by 2020 in Armenia, (b) Sensitivity analysis of cost-coverage for seasonal migrant HIV testing and counselling program in Armenia.](JIAS-18-20416-g001){#F0030_20416}

###### 

Projected number of patients on first- and second-line ART in 2020 and 2030 under various scenarios

                                                                                     2020         2030                                                                       
  -------------------------------------- ------------------------------------------- ------------ ----------- ------------ ----------- ------------ ----------- ------------ -----------
  Accelerated scale-up until universal   No interruptions, immediate switching       18,272,800   2,480,100   19,143,300   1,672,400   19,561,700   4,144,300   20,730,300   2,992,200
  coverage reached                       Interruptions included, delayed switching   18,334,300   1,771,300   18,869,600   1,221,200   20,161,000   3,561,500   21,143,100   2,539,400
  Stable scale-up                        No interruptions, immediate switching       13,306,000   1,899,200   13,807,300   1,387,100   15,717,400   3,239,100   16,397,400   2,555,600
                                         Interruptions included, delayed switching   12,598,600   1,445,300   12,970,000   1,056,600   15,892,600   2,758,100   16,462,900   2,166,900
  No future scale-up                     No interruptions, immediate switching       7,655,600    1,397,200   7,447,200    987,100     7,305,900    1,757,000   7,082,000    1,352,300
                                         Interruptions included, delayed switching   7,697,300    1,186,700   8,009,900    872,700     7,314,800    1,569,200   7,619,000    1,262,700

![Expected number of patients on first- and second-line ART in four selected, unnamed, sub-Saharan African countries. We assumed universal routine viral load monitoring, stable scale-up of ART initiation, and included treatment interruptions and delay in switching. Curves show the model projections and the points the observed numbers. Black/grey curves and points show the total number of patients, blue curves/points the patients on first-line ART and red/pink curves/points the patients on second-line ART.](JIAS-18-20418-g001){#F0031_20418}

![Host Country Government Agency Allocations.](JIAS-18-20559-g001){#F0041_20559}

![ML Tree.](JIAS-18-20424-g001){#F0001_20424}

###### 

Contraceptive effectiveness, by ART status and type

  Progestin use      ART Use   \# Pregnancies   Person-years   Incidence rate (per 100 person-years)   aHR\* (95% CI), reference no contraception   p-value for interaction term
  ------------------ --------- ---------------- -------------- --------------------------------------- -------------------------------------------- ------------------------------
  No contraception   On ART    111              843.5          13.2                                    --                                           --
  No contraception   No ART    1067             4733.6         22.5                                    --                                           --
  Implant            On ART    1                94.1           1.1                                     0.06 (0.01, 0.45)                            0.73
  Implant            No ART    7                507.8          1.4                                     0.05 (0.02, 0.11)                            
  Injectable         On ART    11               332.8          3.3                                     0.18 (0.094, 0.35)                           0.79
  Injectable         No ART    111              2100.2         5.3                                     0.20 (0.16, 0.24)                            
  Oral pills         On ART    5                81.2           6.2                                     0.37 (0.15, 0.91)                            0.97
  Oral pills         No ART    63               573.1          11.0                                    0.36 (0.28, 0.47)                            
  Total                        1376             9266.3         14.8                                    --                                           --

###### 

Congenital anomalies

  Case \#   Description of congenital anomaly   Presenting symptom                                             Timing of diagnosis from birth
  --------- ----------------------------------- -------------------------------------------------------------- --------------------------------
  1         Anovestibular fistula               Stool in urine                                                 42 days
  2         Biliary atresia                     Jaundice at birth                                              48 days
  3         Biliary atresia                     Jaundice at birth                                              38 days
  4         Congenital Lymphedema               Bilateral leg swelling                                         15 days
  5         Jejunal atresia                     Failure to pass stool with abdominal distension and vomiting   5 days
  6         Macrocephaly                        Widening of fontanelle and increasing head size                85 days
  7         Pyloric stenosis                    Projectile vomiting                                            25 days
  8         Talipes equino valgus               Concern expressed by mother about position of foot             60 days

![Distribution of self-reported HIV tests by arm.](JIAS-18-20431-g001){#F0002_20431}

###### 

HIV results among 172 participants in Harare

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                 Participant-read HIVST                       Staff-read HIVST                                                                   Confirmatory test           
  -------------- -------------------------------------------- ---------------------------------------------------------------------------------- --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  HIV negative   146                                          150 (146+3 unsure+1 transcription error[\*](#TF0001_20433){ref-type="table-fn"})   156 (149+7 invalid HIVST)   • 160/172=93% got an accurate HIVST result\
                                                                                                                                                                             • 2/172=1% got an inaccurate HIVST result[\*](#TF0001_20433){ref-type="table-fn"}\
                                                                                                                                                                             • 10/172=6% unable to decipher their HIVST result. 7 (4%) of these had performed the test incorrectly, 3 (2%) could not interpret their result

  HIV positive   16[\*](#TF0001_20433){ref-type="table-fn"}   15                                                                                 16                          

  HIV unsure     5                                            0                                                                                  0                           

  HIV invalid    5                                            7                                                                                  0                           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

One was a participant transcription error -- she was clear in her post-HIVST interview that she thought she was HIV negative. The second was someone on ART who tested negative via self-test and positive in confirmatory testing.

![Uptake of PN services at 22 B + sites.](JIAS-18-20434-g001){#F0003_20434}

![Lowess smooth of the percentage of female methadone clients.](JIAS-18-20438-g001){#F0004_20438}

###### 

Characteristics of perinatally HIV-infected adolescents with non-alcoholic fatty liver disease or liver fibrosis

  Sex     Age (yrs)   BMI (kg/m^2^)   ALT (U/L)   AST (U/L)   Fatty Liver by USG   TE (kPa)   APRI
  ------- ----------- --------------- ----------- ----------- -------------------- ---------- ----------
  **M**   23          **36.2**        **160**     **87**      **Severe**           **14.0**   **0.63**
  F       17          21.3            **36**      24          **Severe**           **5.7**    0.21
  M       15          17.6            **36**      42          **Mild**             **5.9**    0.39
  F       12          15.4            **36**      31          **Mild**             **5.7**    0.42
  F       20          17.8            **46**      35          **Mild**             4.3        0.47
  F       20          20.5            **71**      33          **Mild**             3.3        0.33
  M       17          **25.8**        **50**      45          Normal               **8.6**    **0.60**
  F       18          19.4            23          25          Normal               **8.0**    0.34
  M       14          17.8            23          32          Normal               **7.9**    0.27
  M       18          18.5            29          22          Normal               **7.8**    0.17
  F       23          18.0            19          18          Normal               **7.7**    0.34

M=male; F=female; BMI=body mass index; ALT=alanine aminotransferase; AST=aspartate aminotransferase; USG=ultrasonography; TE=transient elastography; APRI=aspartate aminotransferase-to-platelet ratio index; The bold text indicates abnormal values for each test.

###### 

Baseline characteristics

  Group/parameter (Mean±SD)       I: TDF/FTC/EVG/cobi   II: TDF/FTC + LPV/r   III: TDF/FTC + DRV/r
  ------------------------------- --------------------- --------------------- ----------------------
  Age (years)                     26.3 (±4.8)           27.3 (±4.8)           27.2 (±2.3)
  Weight (kg)                     75.3 (±4.8)           70.2 (±8.3)           72.3 (±7.6)
  Body height (cm)                183.5 (±4.2)          178.9 (±5.7)          180.0 (±5.5)
  BMI (kg/m^2^)                   22.4 (±1.1)           21.9 (±2.2)           22.3 (±1.5)
  Fasting blood glucose (mg/dl)   82.0 (±5.1)           82.3 (±6.7)           83.3 (±6.0)

![Phylogenetic tree of subtype A sequences from PWIDs with evidence for cross-group transmissions plus sequences from the Greek epidemic sampled during 1999--2013 and a randomly selected global sample.](JIAS-18-20449-g001){#F0005_20449}

###### 

Different MSM population size estimates from various methods implemented in Tbilisi, 2014

  PSE method                                                                          Point estimate (18--59y)   Lower bound (18--59y)   Upper bound (18--59y)
  ----------------------------------------------------------------------------------- -------------------------- ----------------------- -----------------------
  Modified capture-Recapture                                                          4385                       3115                    5654
  MSM size -- median of all seven estimates[\*](#TF0001_20452){ref-type="table-fn"}   5100                       3243                    9088
  MSM prevalence in adult population (%)                                              1.42                       0.90                    2.53

Estimates derived from the following methods: Network Scale-Up, Web- and mob-App Multipliers, Service Multiplier, Unique Object Multipliers, RDS-based Handcock, Wisdom of Crowd, Modified Capture-Recapture.

![Testing under various stigma scenarios.](JIAS-18-20454-g001){#F0006_20454}

###### 

Illustrative Quotes

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***Entrenched gender norms***
  • "Men are generally lazy ... 'I am already infected and still want to show my male ego without considering my family' ... many men as well are not ready to take up HIV test and would push their partners to go first and rely on their results." -- Male youth Focus Group Discussion (FGD) participant, Sena
  • "As men we have a lot of fear ... Men also like giving excuses, that they are ever busy in the name of searching for the family, even if they have gotten this food that they are ever looking for \[laughter\]." -- Male adult FGD participant, Sena
  • "Many men believe that medical issues are women\'s affairs." -- Male adult FGD participant, Ongo
  • "Men are people with hardened hearts. They will hardly rush for any programme. They can release their wives and children first to go, and for him, he assesses before going." -- Female adult FGD participant, Kameke
  ***Signs of changing gender norms***
  • Interviewer: "You have mentioned that most people do not test as couples; please tell me more about this?"
  • "A good percentage of men are not faithful. It is men who would even end up enrolling for HIV care at a very far facility. Men should change and be free to test as couples so as to build trust. They should stop frustrating their women as well." \[Female adult participant\]
  • "Gender based violence is real and rampant in this community. This is so because there is no family dialogue to discuss family issues. I do dialogue in my house but when I introduced the HIV topics, many started avoiding the dialogue." \[Male adult participant, FGD Tom Mboya\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Paediatric PMTCT and knowledge of partner status

                                 Unknown partner HIV status   Partner known HIV positive (known concordant relationship) OR (p-value)   Partner known HIV negative (known discordant relationship) OR (p-value)
  ------------------------------ ---------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------
  Infant PCR test                1                            1.96 (0.000)                                                              1.20 (0.261)
  Infant PCR test result         1                            2.12 (0.000)                                                              1.41 (0.022)
  Infant 18 months test          1                            1.89 (0.000)                                                              1.41 (0.012)
  Infant 18 months test result   1                            1.91 (0.000)                                                              1.44 (0.008)
  Infant on ART                  1                            0.84 (0.505)                                                              0.89 (0.751)

###### 

Factors associated with uptake of assisted partner services for HIV testing and HIV diagnosis

  N=278                                 Tested Prior to APS \# (%)   Total Tested at 8 weeks \# (%)   OR testing Post v Pre APS[\*](#TF0001_20457){ref-type="table-fn"} (Univariate)   OR testing Post v Pre APS[\*\*](#TF0002_20457){ref-type="table-fn"} (Multivariate)   HIV+ Prior to APS \# (%)   Total HIV+ at 8 weeks \# (%)   OR HIV+ Post v Pre APS[\*](#TF0001_20457){ref-type="table-fn"} (Univariate)   OR HIV+ Post v Pre APS[\*\*](#TF0002_20457){ref-type="table-fn"} (Multivariate)
  ------------------------------------- ---------------------------- -------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ -------------------------- ------------------------------ ----------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  Male partner (ref: female)            59 (28.8)                    142 (69.3)                       1.61 (0.91--2.84)                                                                                                                                                     33 (15.8)                  78 (38.1)                      1.51 (0.76--2.99)                                                             
  Live together                         66 (43.4)                    124 (81.6)                       1.07 (0.67--1.70)                                                                                                                                                     36 (23.7)                  71 (46.7)                      1.67 (0.92--3.03)                                                             
  IP has \>1 sex partner                37 (27.4)                    73 (54.1)                        0.43 (0.26--0.72)                                                                0.52 (0.31--0.89)                                                                    19 (13.6)                  33 (24.4)                      0.28 (0.15--0.52)                                                             0.39 (0.20--0.77)
  Has continuing sexual relations       78 (35.3)                    172 (77.8)                       2.78 (1.44--5.33)                                                                2.09 (1.04--4.17)                                                                    43 (19.3)                  94 (42.5)                      3.36 (1.27--8.93)                                                             1.92 (0.70--5.53)
  IP reason for HIV testing: symptoms   20 (23.8)                    52 (61.9)                        0.99 (0.58--1.70)                                                                                                                                                     9 (10.6)                   24 (28.6)                      0.74 (0.39--1.39)                                                             
  IP reason for HIV testing: prenatal   44 (37.0)                    96 (80.7)                        1.61 (0.97--2.67)                                                                                                                                                     21 (17.2)                  54 (45.4)                      2.34 (1.30--4.21)                                                             1.66 (0.91--3.03)
  Total                                 89                           192                                                                                                                                                                                                    48                         103                                                                                                          

Results from logistic regression models using the (cluster) option in STATA. 95% CI presented in parentheses.

Results from univariate models.

Results from multivariate models.

![(a) Graphical presentations of patient longitudinal pre-ART data and regression lines obtained from a variable intercept linear mixed effects model showing longitudinal VL differences in infected B\*58:02+vaccinees (blue, n=7) and placebo-recipients (red, n=7); ANOVA. (b) Kaplan-Meier curves showing time to CD4\<350 cells/µl in infected HLA-B\*58:02+vaccinees (blue, n=7) and placebo-recipients (red, n=7); log rank test.](JIAS-18-20461-g001){#F0007_20461}

###### 

Diagnostic Sensitivity and Specificity of the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 Qualitative version 2 compared to the Roche Amplicor HIV-1 DNA PCR assay v1.5

  Roche COBAS Ampliprep/COBAS TaqMan HIV-1 Qualitative version 2 sample type   Sensitivity   Specificity
  ---------------------------------------------------------------------------- ------------- -------------
  Whole blood                                                                  98.5%         100%
  Plasma                                                                       87.0%         100%
  Dried blood spot                                                             98.5%         100%

![Adjusted 12-month log hazard ratios of observed and corrected LTFU from Cox\'s proportional hazards models by CD4 count at ART initiation.](JIAS-18-20467-g001){#F0008_20467}

![Action taken for the sampled patients with viral failure stratified by referral to the treatment failure path-way.](JIAS-18-20468-g001){#F0009_20468}

###### 

Percent of correct classification of VF by WB HIV VL

  Abbott RealTime HIV-1 Plasma VL                     LDL (lower than detectable limit)   Not LDL \<1000 copies/mL   1000--10,000 copies/mL   \>10,000 copies/mL
  --------------------------------------------------- ----------------------------------- -------------------------- ------------------------ --------------------
  N                                                   94                                  52                         52                       101
  Alere q HIV-1/2 WB% correct classification          22%                                 14%                        100%                     100%
  DBS Abbott RealTime HIV-1% correct classification   87%                                 63%                        94%                      100%
  DBS Roche CAP/CTM HIV-1% correct classification     100%                                98%                        0%                       80%

![Flow chart -- assignment of HIV acquisition.](JIAS-18-20472-g001){#F0010_20472}

###### 

France HIV acquisition -- conservative scenario

                                               Men   Women                                                    
  --------------------------- ---------------- ----- ------- ------------ --------- ----- ------ ------------ ---------
  Overall                                      348   43.9    37.4--50.6             550   30.0   25.1--35.4    
  Age at arrival in France    \<25 yr          84    78.1    65.5--87.1   \<0.001   171   54.1   46.5--61.5   \<0.001
                              25--34 yr        139   44.3    35.9--53.2             251   24.5   17.7--32.8    
                              35 yr and more   125   19.8    13.0--28.8             128   8.4    4.4--15.5     
  Number of years in France   0--2             137   10.3    4.9--20.6    \<0.001   254   5.4    3.2--8.9     \<0.001
   prior to diagnosis         3--5             45    19.3    7.0--43.0              93    23.4   18.6--29.0    
                              6--9             39    54.0    36.2--70.9             67    52.5   36.3--68.3    
                              10 or more       106   93.5    85.4--97.3             95    86.0   77.0--91.9    

![HIV prevalence in each of the 40 RCCS communities.](JIAS-18-20474-g001){#F0011_20474}

###### 

Cost-effectiveness projection results

  Intervention                          Total Cost   Incremental Cost   Incremental Cost (including lifetime ART)   DALYs Accumulated   Incremental Effectiveness (DALYs averted)   Incremental Cost-Effectiveness Ratio (ICER)   Incremental Cost-Effectiveness Ratio (ICER) including lifetime ART
  ------------------------------------- ------------ ------------------ ------------------------------------------- ------------------- ------------------------------------------- --------------------------------------------- --------------------------------------------------------------------
  Standard of Care (SOC)                9.12         REFERENCE          REFERENCE                                   8.55                REFERENCE                                   REFERENCE                                     REFERENCE
  CRAG-LFA Screening                    10.58        1.46               139.48                                      8.30                0.25                                        5.88                                          557.60
  Universal Primary Prophylaxis (UPP)   236.23       227.10             332.19                                      8.35                0.20                                        1141.96                                       1660.95

![Decision-analysis model schematic.\
Abbreviations: SOC-Standard of care, UPP-Universal fluconazole primary prophylaxis, CRAG-LFA--cryptococal antigen lateral flow assay, CM-cryptococcal meningitis, WTP-WHO pre-emptive therapy.\
Decision-analytic model schematic. We modeled progression or relapse of CM over a 5 year time-horizon for a cohort of PLWH with CD4 \< 100. In all model arms symptomatic patients at baseline receive evaluation for CM assumed to include a lumbar puncture (LP), and treatment if diagnosed with CM. We assumed ART initiation in all arms. The model explores three interventions for prevention of cryptococcal morbidity for those without a baseline diagnosis of CM: 1) SOC, in which patients receive no CM screening or prophylaxis 2) UPP, in which all asymptomatic patients (and symptomatic patients without CM diagnosis \* as noted in the model) receive primary prophylaxis with 200 mg of fluconazole. 3) CRAG-LFA, in which all patients receive serum CRAG-LFA screening. Individuals with positive CRAG were assumed to receive the WHO preemptive treatment for cryptococcemia with fluconazole 800 mg for two weeks, followed by fluconazole 400 mg for eight weeks. CRAG-negative individuals receive no further antifungal therapy.](JIAS-18-20475-g001){#F0012_20475}

![Definitions of PITC models.](JIAS-18-20476-g001){#F0013_20476}

###### 

Reported PITC model and use of PITC register

                                                                   *Types of PITC reported, n (%)*                               
  ---------------------------------------------------------------- --------------------------------- ------------- ------------- -------------
  TB Clinic                                                        5/12 (42)                         7/12 (58)     0/12 (0)      12/12 (100)
  Antenatal clinic and maternity ward                              20/24 (83)                        4/24 (17)     0/24 (0)      24/24 (100)
  Family planning clinic                                           1/11 (9)                          7/11 (64)     3/11 (27)     8/11 (73)
  STI clinic                                                       3/6 (50)                          3/6 (50)      0/6 (0)       6/6 (100)
  Outpatient Department, Under-5 clinic, and immunization clinic   4/36 (11)                         4/36 (11)     28/36 (78)    9/36 (25)
  Malnutrition clinic                                              7/10 (7)                          2/10 (20)     1/10 (10)     5/10 (50)
  Adult and paediatric inpatient wards                             1/19 (5)                          3/19 (16)     15/19 (79)    5/19 (26)
  Totals                                                           41/118 (35)                       30/118 (25)   47/118 (40)   69/118 (59)

![Trends of EID for HIV in southwestern Uganda: 2011--2014.](JIAS-18-20565-g001){#F0014_20565}

###### 

Summary of INSTI^™^ test results on Commercial HIV-1 Seroconversion Samples before and after IgM removal

                                   Before IgM removal   After IgM removal             
  -------------------------------- -------------------- ------------------- ---- ---- ----
  15 early SC, IgM positives       15                   8                   7    --   --
  6 early SC, IgM not determined   6                    2                   3    1    --
  5 late SC, IgG                   5                    --                  --   --   5
  Total=26                         26                   10                  10   1    5
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